该药企商业化筹备进行时,2026年迎来收获期

制药网
Feb 27

截至2月26日收盘,再鼎医药报收于14.48港元,下跌3.08%,成交量707.99万股,成交额1.05亿港元。消息面上,2月26日,再鼎医药发布公告,公司在2025年实现了财务表现与研发管线的双重突破。2025年Q4,再鼎医药总收入为1.276亿美元,同比增长17%;2025年全年总收入为4.602亿美元,同比增长15%。2025年第四季度净亏损为5040.9万美元,同比收窄38.29%;...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10